Roche Holding AG

Swiss Stock Exchange RO.SW

Roche Holding AG EBITDA Margin for the year ending December 31, 2023: 30.46%

Roche Holding AG EBITDA Margin is 30.46% for the year ending December 31, 2023, a -7.32% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Roche Holding AG EBITDA Margin for the year ending December 31, 2022 was 32.87%, a -6.97% change year over year.
Roche Holding AG EBITDA Margin for the year ending December 31, 2021 was 35.33%, a -10.29% change year over year.
Roche Holding AG EBITDA Margin for the year ending December 31, 2020 was 39.38%, a 16.46% change year over year.
Roche Holding AG EBITDA Margin for the year ending December 31, 2019 was 33.82%, a 9.69% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Swiss Stock Exchange: RO.SW

Roche Holding AG

CEO	Dr. Thomas Schinecker
IPO Date	Aug. 3, 1995
Location	Switzerland
Headquarters	Konzern Hauptsitz
Employees	103,605
Sector	Health Care
Industries Pharmaceuticals

Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Key trends

Past 5 years